Estrigenix Therapeutics

Estrigenix Therapeutics, Inc. presents new hormone replacement therapy research at the 10th Drug Discovery Strategic Summit

MILWAUKEE (Oct. 25, 2022) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, is presenting at the 10th Drug Discovery Strategic Summit on Thursday, October 27, and Friday, October 28 at the Grand Hyatt at San Francisco airport, located at 55 South McDonnell Road in San Francisco.  Estrigenix’s chief executive Estrigenix Therapeutics, Inc. presents new hormone replacement therapy research at the 10th Drug Discovery Strategic Summit

Estrigenix Therapeutics, Inc. presents at American Chemical Society’s Midwest Regional Meeting

MILWAUKEE (Oct. 19, 2022) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, is presenting atthe Midwest Regional Meeting of the American Chemical Society in Iowa City, Iowa on Wednesday, October 19, 2022. William Donaldson, Ph.D., chief executive officer (CEO) of Estrigenix is presenting an abstract entitled, “Discovery Estrigenix Therapeutics, Inc. presents at American Chemical Society’s Midwest Regional Meeting

Estrigenix Therapeutics, Inc. Awarded $300,000 Grant from the National Institute of Health

MILWAUKEE (Oct. 17, 2022) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, has been awarded a $300,000 National Institute of Health (NIH) Small Business Innovation Research (SBIR) Phase I grant. The one-year grant provides funds to support pre-clinical studies on one of Estrigenix’s lead compounds to reduce Estrigenix Therapeutics, Inc. Awarded $300,000 Grant from the National Institute of Health